Icon

VYNDAQEL (nda211996)- (20MG)

TAFAMIDIS MEGLUMINE FOLDRX PHARMS
20MG
Yes No
2025-Dec-19 2024-May-03
None None
None No
VYNDAQEL is transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
0 0 0
Total Other Developers 6
Drugs with Suitability No
20MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.